Pathstone Holdings
ALNY icon

Pathstone Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pathstone Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
7,417
+345
+5% +$104K 0.01% 1054
2026
Q1 		$2.34M Buy
7,072
+933
+15% +$317K 0.01% 949
2025
Q4 		$2.44M Sell
6,139
-158
-3% -$69.9K 0.01% 918
2025
Q3 		$2.87M Buy
6,297
+221
+4% +$90K 0.01% 832
2025
Q2 		$1.98M Sell
6,076
-222
-4% -$61.4K 0.01% 1003
2025
Q1 		$1.7M Buy
6,298
+115
+2% +$29.6K 0.01% 1071
2024
Q4 		$1.45M Sell
6,183
-66
-1% -$17.4K 0.01% 1158
2024
Q3 		$1.72M Buy
6,249
+629
+11% +$164K 0.01% 1069
2024
Q2 		$1.37M Buy
5,620
+1,762
+46% +$278K 0.01% 1127
2024
Q1 		$577K Buy
3,858
+974
+34% +$162K ﹤0.01% 1615
2023
Q4 		$552K Buy
+2,884
New +$491K ﹤0.01% 1439

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's ALNY Position: Q2 2026 in Review

Pathstone Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 4.9% in Q2 2026, buying an estimated $104K and bringing the position to 7,417 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #1054.

Pathstone Holdings first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.87M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Pathstone Holdings held 7,417 shares of Alnylam Pharmaceuticals worth $2.23M as of Q2 2026.
  • Pathstone Holdings bought 345 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $104K.
  • Alnylam Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1054 holding.
  • Pathstone Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Alnylam Pharmaceuticals position peaked at $2.87M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.